Novel emerging biomarkers to immunotherapy in kidney cancer
The treatment of metastatic renal cell carcinoma has significantly evolved in recent years, particularly with the advent of novel immune checkpoint inhibitors (ICI). Despite the striking benefits observed on a population level, outcomes vary and some patients do not respond to ICI-based regimens, ul...
Enregistré dans:
Auteurs principaux: | Yasser Ged, Martin H. Voss |
---|---|
Format: | article |
Langue: | EN |
Publié: |
SAGE Publishing
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/85f04da038e547b387181e4738d986d2 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies
par: Andrew Wallace, et autres
Publié: (2021) -
Cancer immunology and immunotherapy
par: Xiubao Ren
Publié: (2021) -
Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
par: Hong-fen Guo, et autres
Publié: (2021) -
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
par: Amaia Lujambio, et autres
Publié: (2021) -
Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
par: Chuan HUANG, et autres
Publié: (2021)